NewsRx

Search our medical news database

Radioimmunotherapy

Alpha-Emitting Antibodies are Safe In Vivo

Published in Cancer Weekly, March 8th, 1999

Alpha-particle-emitting radionuclides are highly cytotoxic, yet specific and safe in vivo for radioimmunotherapy use.

T.K. Nikula and colleagues from the Memorial Sloan Kettering Cancer Center, New York, described the pharmacokinetic, bioactivity, toxicity and chemical characteristics of cr-particle-emitting, Bi-213 and Bi-212 radiometal conjugated HuM195 (anti-CD33) constructs ("Alpha-Emitting Bismuth Cyclohexylbenzyl DTPA"Alpha-Emitting Bismuth Cyclohexylbenzyl DTPA Constructs of Recombinant Humanized Anti-CD33 Antibodies: Pharmacokinetics, Bioactivity, Toxicity and Chemistry," Journal of Nuclear Medicine, January 1999;40(1):166-176).

"The...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook